Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 259 publications
Prediction of Anthracycline Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study.
Journal: JCO precision oncology
Published: June 24, 2026
Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 17, 2026
Clinically Meaningful, Patient-Centered Endpoints for Real-World Evidence Generation in Breast Cancer: Perspectives from the Multidisciplinary TRIUMPH Initiative.
Journal: Advances in therapy
Published: March 17, 2026
ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.
Journal: Annals of surgical oncology
Published: March 12, 2026
Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 02, 2026
Palbociclib in Patients With HR+/HER2- Advanced or Metastatic Breast Cancer and Bone-Only Metastasis: A Systematic Literature Review.
Journal: Clinical breast cancer
Published: January 14, 2026
Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial.
Journal: NPJ breast cancer
Published: December 03, 2025
Corrigendum to "Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3": [Ann Oncol 2024; 35: 718-727].
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 15, 2025
Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 07, 2025
Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.
Journal: Annals of surgical oncology
Published: October 03, 2025
Last Updated: 09/26/2026